Age-related macular degeneration (AMD) results from a combination of aging biology, genetic susceptibility, and environmental exposures that together damage the central part of the retina. No single cause explains it. Instead, several processes converge over decades: waste products accumulate beneath the retina, the immune system mounts a destructive inflammatory response, and oxidative stress from light exposure and normal metabolism slowly degrades the cells responsible for central vision.
How the Retina Breaks Down Over Time
The macula, the small region at the center of your retina, is one of the most metabolically active tissues in your body. It constantly converts light into electrical signals, and that process generates large amounts of unstable molecules called reactive oxygen species as normal byproducts. The cells that support your photoreceptors, known as retinal pigment epithelium (RPE), sit in an environment with oxygen levels far higher than most tissues, making them especially vulnerable to this kind of chemical damage.
Throughout your life, RPE cells do heavy maintenance work. Each one processes roughly 30,000 shed photoreceptor segments, manages vitamin A metabolism, and regulates the barrier between your retina and its blood supply. All of this generates even more reactive oxygen species. Over decades, the cellular machinery that neutralizes these damaging molecules becomes less efficient, and the cumulative toll starts to show.
One visible result is drusen, the yellowish deposits that appear beneath the retina in early AMD. These form because cholesterol-rich particles secreted from the base of RPE cells gradually accumulate on a thin membrane that separates the retina from its blood supply. Small drusen are common and often harmless, but as they grow larger, they interfere with the nutrient exchange that keeps photoreceptors alive.
The Role of Light and Oxidative Stress
Your macula is directly exposed to incoming light, and certain wavelengths actively generate damaging molecules in retinal tissue. Ultraviolet light (100 to 400 nanometers) and blue light (400 to 500 nanometers) are particularly harmful, triggering photochemical reactions that produce reactive oxygen species in both photoreceptors and the RPE cells beneath them. Blue light exposure can ramp up this damage within 30 minutes to an hour in retinal tissue.
The damage isn’t abstract. These reactive molecules attack lipids, proteins, and DNA inside cells. Over years of exposure, the mitochondria inside RPE cells, which serve as the cells’ power plants, become a major source of the problem. As mitochondria deteriorate with age, they leak more damaging molecules, creating a feedback loop: oxidative damage impairs the very structures meant to protect against it.
Chronic Inflammation Accelerates the Damage
One of the most important discoveries in AMD research is that the immune system plays a central role in driving the disease forward. Specifically, a part of the immune system called the complement cascade, which normally targets bacteria and debris for destruction, becomes overactive in the aging retina.
In a healthy eye, complement proteins help clear waste. In AMD, this system becomes dysregulated and begins attacking the retina’s own tissue. Complement activation produces signaling molecules that recruit immune cells, including macrophages and mast cells, to the space around the RPE. These cells release enzymes that degrade the surrounding tissue, and mast cells release proteins that remodel the structural framework of the retina. The result is a state of chronic, low-grade inflammation at the boundary between the retina and its blood supply.
In late-stage AMD, structures called membrane attack complexes, which the complement system normally uses to punch holes in bacteria, begin forming near RPE cells themselves. Early in the disease, RPE cells seem to tolerate some of this assault. But over time, the combination of complement-driven inflammation, immune cell infiltration, and oxidative stress overwhelms them. RPE cells degenerate, and the photoreceptors they support begin to fail.
Genetics Set the Stage
Two genetic regions contribute more to AMD risk than any others. Variations in the CFH gene and in the ARMS2/HTRA1 region each independently raise your likelihood of developing the disease. CFH encodes a protein that normally keeps complement activation in check. When this gene carries certain variants, that braking mechanism weakens, allowing the inflammatory cascade described above to run hotter than it should.
The combined effect of genetic and inflammatory risk factors is substantial. People who carry high-risk variants in both CFH and ARMS2/HTRA1 and also have elevated levels of C-reactive protein, a marker of systemic inflammation, face roughly five times the risk of developing AMD compared to those without these factors. Genetics alone don’t determine your outcome, but they set the threshold for how much environmental damage your retina can absorb before disease develops.
A study of identical twins with different AMD outcomes confirmed that genetics aren’t the whole story. Twins who smoked had twice the risk of developing AMD as their nonsmoking sibling, despite sharing the same DNA. This points to epigenetic and environmental factors that operate on top of inherited risk.
Smoking Is the Strongest Modifiable Risk Factor
After age itself, smoking is the most consistently demonstrated risk factor for AMD. Current smokers face a two- to fourfold increase in risk compared to people who have never smoked. Women who smoked 25 or more cigarettes per day had 2.4 times the risk of developing AMD in the Nurses’ Health Study.
Smoking damages the retina through multiple pathways at once. It increases oxidative stress, reduces blood flow to the choroid (the vascular layer beneath the retina), lowers levels of protective antioxidants in the blood, and promotes the kind of systemic inflammation that activates the complement cascade. These effects compound over years, which is why cumulative pack-years of smoking correlate with disease severity.
Obesity and Body Weight
Carrying excess weight raises your risk of developing late-stage AMD specifically. Obese individuals have a 32% higher risk of late AMD compared to those at a normal weight. For every one-point increase in BMI above the overweight threshold, AMD risk rises by about 2%. Interestingly, obesity does not appear to increase the risk of early-stage AMD, suggesting that excess body weight may specifically accelerate the transition from early disease to vision-threatening late disease.
Age Is the Primary Driver
The prevalence numbers make the impact of age starkly clear. Among Americans on Medicare aged 65 to 84, roughly 7 to 8% have AMD. Among those 85 and older, that figure jumps to 21 to 24%. Across all adults 40 and older, about 12% show signs of early-stage disease, while just under 1% have progressed to late-stage AMD.
Age drives AMD because every mechanism described above is time-dependent. Drusen accumulate gradually. Oxidative damage compounds. The complement system drifts toward overactivation. Mitochondrial function declines. None of these processes have a clear starting gun. They simply accelerate with each passing decade until the retina’s defenses are outpaced by the damage.
How Dry AMD Becomes Wet AMD
About 80 to 90% of AMD cases are the dry form, which progresses slowly as RPE cells deteriorate and photoreceptors lose support. In its most advanced stage, called geographic atrophy, patches of RPE and photoreceptors die completely, leaving blank spots in central vision. Clinicians now define this progression based on imaging that shows complete loss of the RPE and the outer retinal layers above it.
Wet AMD develops when the damage triggers a more aggressive response. As RPE cells and the surrounding tissue become oxygen-starved, they activate a protein called vascular endothelial growth factor (VEGF). Under normal conditions, low oxygen causes cells to ramp up VEGF production, signaling the body to grow new blood vessels. In wet AMD, this signal draws new, fragile blood vessels from the choroid up through the damaged membrane and into the retinal space.
These new vessels are structurally defective. Their walls leak fluid and blood into the retina, causing rapid swelling and distortion of central vision. Immune cells recruited to the site release inflammatory signals that synergize with VEGF, driving further vessel growth and worsening the damage. This is why wet AMD can cause sudden, dramatic vision loss compared to the gradual decline of dry AMD, even though both forms share the same underlying causes.
Nutrients That Slow Progression
While no supplement prevents AMD from starting, a specific combination of nutrients has been shown to slow progression from intermediate to advanced disease. The AREDS2 formula, developed through large clinical trials funded by the National Eye Institute, reduced the risk of advancing to late AMD by about 25% over five years. The formula contains 500 mg of vitamin C, 400 IU of vitamin E, 80 mg of zinc, 2 mg of copper (to offset zinc-related copper deficiency), 10 mg of lutein, and 2 mg of zeaxanthin.
Lutein and zeaxanthin are particularly relevant because they concentrate naturally in the macula, where they act as a filter for blue light and as antioxidants. Participants with the lowest dietary intake of these two nutrients saw the greatest benefit from supplementation, with a 26% lower risk of progression compared to those on the older formula. The original AREDS formula contained beta-carotene instead, but this was replaced because beta-carotene increases lung cancer risk in current and former smokers.